Impact of drug transporter studies on drug discovery and development

Pharmacological Reviews

Volumn 55, Issue 3, 2003, Pages 425-461

  Mizuno, Naomi ^b   Niwa, Takuro ^b   Yotsumoto, Yoshihisa ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT EXPORT PUMP; ENZYME; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PROTEIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INTERACTION; DRUG SAFETY; DRUG TRANSPORT; GENETIC POLYMORPHISM; MULTIDRUG RESISTANCE; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SEX DIFFERENCE; SPECIES DIFFERENCE; TRANSCRIPTION REGULATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CARRIER PROTEINS; DRUG DESIGN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; KIDNEY; LIVER; MALE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS; SPECIES SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 0042468096     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.55.3.1     Document Type: Review

References (386)

1. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, et al. (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159-17163.
2. Abu-Zahra TN, Wolkoff AW, Kim RB, and Pang KS (2000) Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes: role of organic anion transporting polypeptide. Drug Metab Dispos 28:801-806.
3. Achim CL, Wang R, and Miners DK (1994) Brain viral burden in HIV infection. J Neuropathol Exp Neurol 53:284-294.
4. Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res (NY) 18:1660-1668.
5. Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, and Sugiyama Y (2001) Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim Biophys Acta 1511:7-16.
6. Alexandridis G, Pappas GA, and Elisaf MS (2000) Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 109:261-262.
7. Alsenz J, Steffen H, and Alex R (1998) Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res (NY) 15:423-428.
8. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githangs J, Indalo A, et al. (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11:217-221
9. Amsden GW, Nafziger AN, Foulds G, and Cabelus LJ (2000) A study of the pharmacokinetics of azithromycin and nelfinavir when coadministrated in healthy volunteers. J Clin Pharmacol 40:1522-1527.
10. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorg DJ, and Suchy FJ (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 276:28857-28865.
11. Andreana A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, and Gupta S (1996) Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 11:893-901.
12. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, and Endou H (1999) Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol 55:847-854.
13. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, and Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697-702.
14. Asaba H, Hosoya K, Takanaga H, Ohtsuki S, Tamura E, Takizawa T, and Terasaki T (2000) Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J Neurochem 75:1907-1916.
15. Ayrton A and Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
16. Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, and Shinko PJ (1998) Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 250:246-251.
17. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, and Abul-Ezz SR (2000) Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother 34:1013-1016.
18. Bergwerk AJ, Shi X, Ford AC, Kanai N, Jacquemin E, Burk RD, Bai S, Novikoff PM, Stieger B, Meier PJ, et al. (1996) Immunologic distribution of an organic anion transport protein in rat liver and kidney. Am J Physiol Gastrointest Liver Physiol 271:G231-G238.
19. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208-12213.
20. Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgaetner G, and Dombrowski F (2001) Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 35:1206-1216.
21. Bezprozvanny I and Maximov A (2001) PDZ domains: more than just a glue. Proc Natl Acid Sci USA 98:787-789.
22. Blumberg B, Sabbagh W Jr, Jugulion H, Bolado J Jr, van Meter CM, Ong ES, and Evans RM (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205.
23. Borst P, Evers R, Kool M, and Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347-357.
24. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, and Whitfield L (2000) Atrovastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 40:91-98.
25. Breidert T, Spitzenberger F, Grundemann D, and Schomig E (1998) Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol 125:218-224.
26. Britten CD, Baker SD, Denis LJ, Johnson T, Drengler R, Siu LL, Duchin K, Kuhn J, and Rowinsky EK (2000) Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. Clin Cancer Res 6:3459-3468.
27. Briz O, Serrano MA, Rebollo N, Hagenbuch B, Meier PJ, Koepsell H, and Marin JJG (2002) Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(IT) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol 61:853-860.
28. Bu H, Poglod M, Micetich RG, and Khan JK (2000) High-throughput Caco-2 cell permeability screening by cassette dosing and sample pooling approaches using direct injection/on-line guard cartridge extraction/tandem mass spectrometry. Rapid Commun Mass Spectrom 14:523-528.
29. Buist SCN, Cherrington NJ, Choudhuri S, Hartley DP, and Klaassen CD (2002) Gender-specific and developmental influence on the expression of rat organic anion transporters. J Pharmacol Exp Ther 301:145-151.
30. Burckhardt G and Wolff NA (2000) Structure of renal organic anion and cation transporters. Am J Physiol Renal Physiol 278:F853-F866
31. Calvo MV, Martin-Suarez A, Martin Luengo C, Avila C, Cascon M, and Dominguez-Gil Hurle A (1989) Interaction between digoxin and propafenone. Ther Drug Monit 11:10-15.
32. Cascorbi I, Gerlogg T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, and Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174.
33. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, and Endou H (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286.
34. Chang T, Benet LZ, and Hebert MF (1996) The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 59:297-303.
35. Charatan F (2001) Bayer decides to withdraw cholesterol lowering drug. BMJ 323:359.
36. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of p-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
37. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, and Sugiyama Y (1997b) Multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of the camptothecin derivative irinotecan, CPT-11 and its metabolites in rats. J Pharmacol Exp Ther 281:304-314.
38. Chu XY, Kato Y, and Sugiyama Y (1997a) Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan, CPT-11 and its metabolites in rats. Cancer Res 57:1934-1938.
39. Chu X, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, et al. (1998) Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res 58:5137-5143.
40. Cihlar T and Ho ES (2000) Florescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem 283:49-55.
41. Cihlar T, Ho ES, Lin DC, and Mulato AS (2001) Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides 20:641-648.
42. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, and Sweet DH (1999) The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56:570-580.
43. Cobbe SM (1997) Using the right drug. A treatment algorithm for atrial fibrillation. Eur Heart J 18(Suppl C):33-39.
44. Cole SP and Deeley RG (1998) Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20:931-940.
45. Cui Y, Konig J, and Keppler D (2001a) Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60:934-943.
46. Cui Y, Konig J, Leier I, Buchholz U, and Keppler D (2001b) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
47. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
48. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
49. Dantzig AH, Law KL, Cao J, and Starling IJ (2001) Reversal of multidrug resistance by the P-glycoprotein modulator, LY335989, from the bench to the clinic. Curr Med Chem 8:39-50.
50. Davit B, Reynolds K, Yuan R, Ajayi P, Conner D, Padiran E, Gillespir B, Sahajwalla C, Huang S, and Lesko LJ (1999) FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling. J Clin Pharmacol 39:899-910.
51. de Bruin M, Miyake K, Litman T, Robey R, and Bates SE (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117-126.
52. de Lange ECM, de Bock G, Schinkel AH, de Boer AG, and Breimer DD (1998) BBB transport and P-glycoprotein functionality using MDRla (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of Rhodamine-123. Pharm Res (NY) 15:1657-1665.
53. Desrayaud S, de Range ECM, Lemaire M, Bruelisauer A, de Boer AG, and Breimer DD (1998) Effect of the mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice. J Pharmacol Exp Ther 285:438-443.
54. Doan KMM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
55. Dominguez MF, Macias RIR, Izco-Basurko I, Fuente ADL, Pascual MJ, Craido JM, Monte MJ, Yajeya J and Marin JJG (2001) Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J Pharmacol Exp Ther 297:1106-1112.
56. Donner MG and Keppler D (2001) Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 34:351-359.
57. Doppenschmitt S, Spahn-Langguth H, Regardh CG, and Langguth P (1998) Radio-ligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter. Pharm Res (NY) 15:1001-1006.
58. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 915:15665-15670.
59. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, and Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20.
60. Dresser MJ, Leabman MK, and Giacomini KM (2001) Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90:397-421.
61. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, and Pattinger K (2000) St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
62. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, and Forman BM (2001) Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276:33309-33312.
63. Ekins S and Erickson JA (2002) A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 30:96-99.
64. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan L, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002a) Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964-973.
65. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan L, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002b) Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981.
66. Ekins S, Mirny L, and Schuetz EG (2002c) A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRα and LXRβ. Pharm Res (NY) 19:1788-1800.
67. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrignton SA, and Wikel JH (2000) Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44:251-272.
68. Eneroth A, Astrom E, Hoogstaate J, Schrenk D, Conrad S, Kauffmann HM, and Gjellan K (2001) Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci 12:205-214.
69. Faber KN, Muller M, and Jansen PLM (2003) Drug transport proteins in the liver. Adv Drug Deliv Rev 55:107-124.
70. Fernandes PB (1998) Technological advances in high-throughput screening. Curr Opin Chem Biol 2:597-603.
71. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, et al. (2001) Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121:170-183.
72. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
73. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
74. Forman BM (2001) Polymorphisms in promiscuous PXR: an explanation for interindividual differences in drug clearance? Pharmacogenetics 11:551-552.
75. Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, and Stiller CR (1987) Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol 23:776-778.
76. Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69-74.
77. Fromm MF (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54:1295-1310.
78. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, and Schrenk D (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575-1580.
79. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, and Gasser R (2001a) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the fender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83-98.
80. Funk C, Ponelle C, Scheuermann G, and Pantze M (2001b) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627-635.
81. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, and Meier PJ (2000) Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73-79.
82. Gao B and Meier PJ (2001) Organic anion transport across the choroid plexus. Microsc Res Tech 52:60-64.
83. Gao J, Murase O, Schowen RL, Aube J, and Borchardt RT (2001) A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res (NY) 18:171-176.
84. Gao B, Stieger B, Noe B, Fritschy JM, and Meier PJ (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264.
85. Geick A, Eichelbaum M, and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
86. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, and Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273:10046-10050.
87. Gomi A, Masuzawa T, Ishikawa T, and Kuo MT (1997) Posttranscriptional regulation of MRP/GS-X pump and gamma-glutamylcysteine synthetase expression by 1-(4-amino-2-methyl-5-pylimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea and by cycloheximide in human glioma cells. Biochem Biophys Res Commun 239:51-56.
88. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, and Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871-881.
89. Gotoh Y, Kato Y, Stieger B, Meier PJ, and Sugiyama Y (2002) Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17β-D-glucuronide in rats. Am J Physiol Endocrinol Metab 282:E1245-E1254.
90. Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, and Sugiyama Y (2000) Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther 292:433-439.
91. Greiner B, Eichelbaum M, Fritz P, Kreichigauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104:147-153.
92. Groothuis DR and Levy RM (1997) The entry of antiviral and antiretroviral drugs into the central nervous system. J Neuroviral 3:387-400.
93. Grub S, Bryson H, Goggin T, Ludin E, and Jorga K (2001) The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 57:115-121.
94. Grundemann D, Gorboulev V, Gambaryan M, Veyhl M, and Koepsell H (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature (Lond) 372:549-552.
95. Guo GL, Staudinger J, Ogura Y, and Klaassen CD (2002) Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol Pharmacol 61:832-839.
96. Gupta SK, Bakran A, Johnson RWG, and Rowland M (1988) Erythromycin enhances the absorption of cyclosporin. Br J Clin Pharmacol 25:401-402.
97. Gupta SK, Bakran A, Johnson RWG, and Rowland M (1989) Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 27:475-481.
98. Hagenbuch B, Gao B, and Meier PJ (2002) Transport of xenobiotics across the blood-brain barrier. News Physiol Sci 17:231-234.
99. Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18.
100. Hagenbuch B, Stieger B, Foguet M, Lubbert H, and Meier PJ (1991) Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci USA 88:10629-10633.
101. Hamman MA, Bruce MA, Haehner-Daniels BD, and Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114-121.
102. Han Y, Kato Y, Harashima M, Ohta M, Matsuoka H, and Sugiyama Y (2001) Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). Pharm Res (NY) 18:579-586.
103. Harris MJ, Kuwano M, Webb M, and Board PG (2001) Identification of the apical membrane targeting signal of the multidrug resistance-associated protein 2 (MRP2/MOAT). J Biol Chem 276:20876-20881.
104. Hasegawa M, Kusuhara H, Endou H, and Sugiyama Y (2003) Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives. J Pharmacol Exp Ther 305:1087-1097.
105. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, and Sugiyama Y (2002) Functional involvement of rat organic anion transporter 3 (rOAT3) in the renal uptake of organic anions. J Pharmacol Exp Ther 300:746-753.
106. Hashida T, Masuda S, Umemoto S, Saito H, Tanaka K, and Inui K (2001) Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 69:308-316.
107. Hebert MF, Fisher RM, Marsh CL, Dressler D, and Bekersky I (1999) Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39:91-96.
108. Hebert UF and Lam AY (1999) Diltiazem increases tacrolimus concentrations. Ann Pharmacother 33:680-682.
109. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson M, and Schenck-Gustafsson K (1991) Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 49:256-262.
110. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, and Nilsson B (1990) Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 47:20-26.
111. Hendrikse NH, Bart J, de Vries EG, Groen HJ, van der Graaf WT, and Vaalburg W (2001) P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography. J Clin Pharmacol (Suppl):48S-54S.
112. Hendrikse NH, Schinkel AH, De Vries EGE, Fluks E, Van der Graaf WTA, Willemsen ATM, Vaalburg W, and Franssen EJF (1998) Complete in-vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418.
113. Henney JE (2000) Risk of drug interactions with St. John's wort. J Am Med Assoc 283:1679.
114. Hirohashi T, Suzuki H, Chu XY, Tamai I, Tsuji A, and Sugiyama Y (2000a) Functional and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J Pharmacol Exp Ther 292:265-270.
115. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, and Sugiyama Y (1998) Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Mol Pharmacol 53:1068-1075.
116. Hirohashi T, Suzuki H, and Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 274:15181-15185.
117. Hirohashi T, Suzuki H, Takikawa H, and Sugiyama Y (2000b) ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 275:2905-2910.
118. Hoetelmans RMW (1998) Sanctuary site in HIV-1 infection. Antivir Ther 3 (Suppl 4):13-17.
119. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
120. Hooiveld GJ, van Montfoort JE, Meijer DY, and Muller M (2001) Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur J Pharm Sci 12:525-543.
121. Hori R, Tomita Y, Katsura T, Yasuhara M, Inui K, and Takano M (1993) Transport of bestatin in rat renal brush-border membrane vesicles. Biochem Pharmacol 45:1763-1768.
122. Horikawa M, Kato Y, and Sugiyama Y (2002a) Reduced gastrointestinal toxicity in rats following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid. Pharm Res (NY) 19:1345-1353.
123. Horikawa M, Kato Y, Tyson CA, and Sugiyama Y (2002b) The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: Probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metabol Pharmacokin 17:23-33.
124. Horikawa M, Kato Y, Tyson CA, and Sugiyama Y (2003) Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet 18:16-22.
125. Hosoyamada M, Sekine T, Kanai Y, and Endou H (1999) Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol Renal Physiol 276:F122-F128.
126. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). J Biol Chem 274:37161-37168.
127. Hsu A, Granneman R, Cao G, Carothers L, El-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, and Leonard JM (1998) Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir, and saquinavir. Clin Pharmacol Ther 63:453-464.
128. Huisman MT, Smit JW, and Schinkel AH (2000) Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14:237-242.
129. Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, and Schinkel AH (2003) Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J Pharmacol Exp Ther 304:596-602.
130. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen JH, and Schinkel AH (2001) P-glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806-813.
131. Hunter J and Hirst BH (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 25:129-157.
132. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, et al. (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454-1459.
133. Iida A, Saito S, Sekine S, Mishima C, Kondo K, Kitamura Y, Harigae S, Osawa S, and Nakamura Y (2001) Catalog of 268 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides and three NADH:ubiquinone oxidoreductase flavoproteins. J Hum Genet 46:668-683.
134. International Human Genome Sequencing Consortium (2001) Initial sequencing and analysis of the human genome. Nature (Lond) 409:860-921.
135. Inui K, Masuda S, and Saito H (2000a) Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58:944-958.
136. Inui K, Terada T, Masuda S, and Saito H (2000b) Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol Dial Transplant 15:11-13.
137. Ishikawa T (1992) The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 17:463-468.
138. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, and Kuo MT (1996) Coordinate induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271:14981-14988.
139. Ishikawa T, Kuo MT, Furuta K, and Suzuki M (2000) The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design. Clin Chem Lab Med 38:893-897.
140. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Stieger B, Meier PJ, and Sugiyama Y (1998) Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 287:37-42.
141. Ishizuka H, Konno K, Naganuma H, Sasahara K, Kawahara Y, Niinuma K, Suzuki H, and Sugiyama Y (1997) Temocaprilat, a novel angiotensin converting enzyme inhibitor, is excreted into bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyper-bilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 280:1304-1311.
142. Ishizuka H, Konno K, Shiina T, Naganuma H, Nishimura K, Ito K, Suzuki H, and Sugiyama Y (1999) Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 290:1324-1330.
143. Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, and Kullak-Ublick GA (2001) Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 121:1185-1190.
144. Ito K, Iwatsubo T, Kanamitsu S, Ueda H, Suzuki H, and Sugiyama Y (1998a) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-411.
145. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, and Sugiyama Y (1998b) Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver. J Biol Chem 273:1684-1688.
146. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, and Sugiyama Y (1997) Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol Gastrointest Liver Physiol 272:G16-G22.
147. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, and Schunack W (1995) Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 58:532-541.
148. Jalava KM, Partanen J, and Neuvonen PJ (1997) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609-613.
149. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, and Endou H (1999) The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther 290:672-677.
150. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, and Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort. Clin Pharmacol Ther 66:338-345.
151. Jonker JW, Smit JW, Brinkhuis RF, Maliepaaed M, Beijnen JH, Schellens JHM, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
152. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, and Schinkel AH (2001) Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 21:5471-5477.
153. Jonker JW, Wagenaar E, van Deemter L, Gottschlich R, Bender HM, Dasenbrock J, and Schinkel AH (1999) Role of blood-brain barrier P-glycoprotein
154. Jung D, Hagenbush B, Gresh L, Pontoglio M, Meier PJ, and Kullak-Ublick GA (2001a) Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J Biol Chem 276:37206-37214.
155. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, and Endou H (2001b) Characterization of ochratoxin A transport by human organic anion transporters. Life Sci 69:2123-2135.
156. Kakyo M, Unno M, Tokui T, Nakagomi R, Nishio T, Iwasashi H, Nakai D, Seki M, Suzuki M, Naitoh T, et al. (1999) Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1. Gastroenterology 117:770-775.
157. Kaneda N and Yokokura T (1990) Nonlinear pharmacokinetic of CPT-11 in rats. Cancer Res 50:1721-1725.
158. Kaplan B, Meier-Kriesche HU, Napoli KL, and Kahan BD (1998) The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 63:48-53.
159. Kartenbeck J, Leuschner U, Mayer R, and Keppler D (1996) Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23:1061-1066.
160. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, and Edwards PA (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor and constitutive androstane receptor. J Biol Chem 277:2908-2915.
161. Kato Y, Kuge K, Kusuhara H, Meier PJ, and Sugiyama Y (2002) Gender difference in the urinary excretion of organic anions in rats. J Pharmacol Exp Ther 302:483-489.
162. Kauffmann HM, Pfarmschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI, and Schrenk D (2002) Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 171:137-146.
163. Kaukonen KM, Olkkola KT, and Neuvonen PJ (1997) Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 62:510-517.
164. Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, and Sugiyama Y (2000) Selective inhibition of human cytochrome P450 3A4 by N-(2(R)-hydroxy-l(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl) -4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R) -phenylmethylpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos 28:1238-1243.
165. Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, and Keppler D (2000) Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 32:1317-1328.
166. Kekuda R, Prasad PD, Wu X, Wand H, Fei YJ, Leibach FH, and Ganapathy V (1998) Cloning and functional characterization of a potential-sensitive polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 273:15971-15979.
167. Keppler D and Konig J (2000) Hepatic secretion of conjugated drugs and endogenous substance. Semin Liver Dis 20:265-272.
168. Keppler D, Konig J, and Buchler M (1997) The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocyte. Adv Enzyme Regul 37:321-333.
169. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, Keil A, Eichelbaum M, and Koepsell H (2002) Identification of genetic variants of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12:591-595.
170. Kerb R, Hoffmeyer S, and Brinkmann U (2001) ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenetics 2:51-64.
171. Kikuchi S, Hata M, Fukumoto K, Yamane Y, Matsui T, Tamura A, Yonemura S, Yamagishi H, Keppler D, Tsukita S, et al. (2002) Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat Genet 31:320-325.
172. Kim RB (2000) Transporters in drug disposition. Curr Opin Drug Discov Develop 3:94-101.
173. Kim RB (2002) MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12:425-427.
174. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
175. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199.
176. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (NY) 16:408-414.
177. Kleizen B, Braakman I, and de Jonge HR (2000) Regulated trafficking of the CFTR chloride channel. Eur J Cell Biol 79:544-556.
178. Kobayashi Y, Horikawa N, Ohshiro N, Sekine T, Sasaki T, Tokuyama S, Endou H, and Yamamoto T (2002) Differential gene expression of organic anion transporters in male and female rats. Biochem Biophys Res Commun 290:482-487.
179. Kocher O, Comella N, Gilchrist A, Pal R, Tognazzi K, Brown LF, and Knoll JH (1999) PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. Lab Investig 79:1161-1170.
180. Koepsell H (1998) Organic cation transporters in intestine, kidney, liver and brain. Annu Rev Physiol 60:243-266.
181. Kojima R, Sekine T, Kawachi M, Cha SH, Suzuki Y, and Endou H (2002) Immunolocalization of multispecific organic anion transporters OAT1, OAT2 and OAT3, in rat kidney. J Am Soc Nephrol 13:848-857.
182. Kolson DL, Lavi E, and Gonzalez-Scarano F (1998) The effects of human immunodeficiency virus in the central nervous system. Adv Virus Res 50:1-47.
183. Konig J, Cui Y, Nies AT, and Keppler D (2000a) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156-G164.
184. Konig J, Cui Y, Nies AT, and Keppler D (2000b) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161-23168.
185. Konig J, Nies AT, Cui Y, Leier I, and Keppler D (1999a) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377-394.
186. Konig J, Rost D, Cui Y, and Keppler D (1999b) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29:1156-1163.
187. Kool M, van der Linden M, de Haas M, Scheer GL, de Vree JML, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, et al. (1999) MRP3 and organic anion transporter able to transport anticancer drugs. Proc Natl Acad Sci USA 96:6914-6919.
188. Kovarik JM, Purba HS, Pongowski M, Gerbeau C, Humbert H, and Mueller EA (1998) Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. Pharmacotherapy 18:1230-1236.
189. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, and Rost KL (1999) Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 66:391-400.
190. Kremer JM and Hamilton RA (1995) The effects of nonsteroidal anti-inflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 22:2072-2077.
191. Kubitz R, Huth C, Schmitt M, Horbach A, Kullak-Ublick G, and Haussinger D (2001) Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells. Hepatology 34:340-350.
192. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533.
193. Kullak-Ublick GA, Stieger B, Hagenbuch B, and Meier PJ (2000) Hepatic transport of bile salts. Semin Liver Dis 20:273-292.
194. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, and Endou H (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274:13675-13680.
195. Kusuhara H and Sugiyama Y (2001a) Drug-drug interactions involving the membrane transport process, in Drug-Drug Interactions (Rodrigues AD ed) pp. 123-188, Marcel Dekker, New York.
196. Kusuhara H and Sugiyama Y (2001b) Efflux transport system for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Parts 1, 2). Drug Discov Today 6:150-156 (1), 206-212 (2).
197. Kusuhara H and Sugiyama Y (2002) Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Controlled Release 78:43-54.
198. Kusuhara H, Suzuki H, and Sugiyama Y (1998) The role of P-glycoprotein and canalicular multispecific organic anion transporter (cMOAT) in the hepatobillary excretion of drugs. J Pharm Sci 87:1025-1040.
199. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, and Sugiyama Y (1997) P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283:574-580.
200. Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, and Wada M (1999) Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 14:123-131.
201. Lautier D, Canitrot Y, Deeley RG, and Cole SP (1996) Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52:967-977.
202. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Clark AG, Herskowitz I, et al. (2002) Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. J Hum Genet 46:668-683.
203. Lee G, Dallas S, Hong M, and Bendayan R (2001a) Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 53:569-596.
204. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, and Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
205. Lee VH, Sporty JL, and Fandy TE (2001b) Pharmacogenomics of drug transporters: the next drug delivery challenge. Adv Drug Deliv Rev 50:S33-S40.
206. Lentz K, Polli JW, Wring SA, Humphreys JE, and Polli JE (2000) Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res (NY) 17: 1456-1460.
207. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81.
208. Lo YL, Hsu CY, and Huang JD (1998) Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line. Anticancer Res 18:3005-3009.
209. Lu R, Kanai N, Bao Y, Wolkoff AW, and Schuster VL (1996) Regulation of renal oatp mRNA expression by testosterone. Am J Physiol Renal Physiol 270:F332-F337.
210. Lucia MB, Cauda R, Landay AL, Malorni W, Donelli G, and Ortona L (1995) Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. AIDS Res Hum Retroviruses 11:893-901.
211. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, and Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase 1 trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642.
212. Mackstaller LL and Alpert JS (1997) Atrial fibrillation: a review of mechanism, etiology and therapy. Clin Cardiol 20:640-650.
213. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg ACLM, Schinkel AH, van de Vijver MJ, Scheper RJ, and Schellens JHM (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
214. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, and Schellens JH (2001a) Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84:42-47.
215. Malingre MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Huinink WWTB, Schot ME, and Schellens JHM (2001b) Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19:1160-1166.
216. Martel F, Vetter T, Russ H, Grundemann D, Azevedo I, Koepsell H, and Schomig E (1996) Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn-Schmiedeberg's Arch Pharmacol 354:320-326.
217. Masereeuw R and Russel FGM (2001) Mechanisms and clinical implications of renal drug excretion. Drug Metab Rev 33:299-351.
218. Masuda M, Iizuka Y, Yamazaki M, Nishigaki R, Kato Y, Niinuma N, Suzuki H, and Sugiyama Y (1997) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 57:3506-3510.
219. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, and Inui K (2000) Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 69:93-103.
220. Maxwell DL, Gilmour-White SY, and Hall NM (1989) Digoxin toxicity due to interaction of digoxin with erythromycin. Br Med J 298:572.
221. Mayatepek E, Nezu J, Tamai I, Oku A, Katsura M, Shimane M, and Tsuji A (2000) Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency. Hum Mutat 15:118.
222. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, and Schinkel AH (1997) Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Investig 100: 2430-2436.
223. Meerum Terwogt JM, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, and Schellens JH (1999) Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5:3379-3384.
224. Meier PJ (1995) Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Am J Physiol Gastrointest Liver Physiol 269:G801-GG812.
225. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, and Stieger B (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667-1677.
226. Meijer DK, Hooiveld GJ, Schinkel AH, van Montfoort JE, Haas M, de Zeeuw D, Moolenaar F, Smit JW, and Meier PJ (1999) Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. Nephrol Dial Transplant 14:1-3.
227. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM, and Back DJ (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
228. Meyer-Wentrup F, Karback U, Gorvoulev V, Arndt P, and Koepsell H (1998) Membrane localization of the electrogenic cation transporter roct1 in rat liver. Biochem Biophys Res Commun 248:673-678.
229. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, and Konig J (2002) A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277:43058-43063.
230. Mistry P, Stewart AJ, Dangerfield W, Okbi S, Liddle C, Bootle D, Plumb JA, Templeton D, and Charlton P (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749-758.
231. Mizuno N and Sugiyama Y (2002) Drug transporters: their role and importance in the selection and development of new drugs. Drug Metabol Pharmacokin 17:93-108.
232. Morita N, Kusuhara H, Sekine T, Endou H, and Sugiyama Y (2001) Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther 298:1179-1184.
233. Moyer BD, Denton J, Karlson KH, Reynolds D, Wang S, Mickle JE, Milewski M, Cutting GR, Guggino WB, Li M, et al. (1999) A PDZ-interacting domain in CFTR is an apical membrane polarization signal. J Clin Investig 104:1353-1361.
234. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, et al. (1999) Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65:251-261.
235. Muck W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, and Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Phamacol Ther 35:255-260.
236. Mulato AS, Ho ES, and Cihlar T (2000) Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 295:10-15.
237. Muller M and Jansen PL (1997) Molecular aspects of hepatobiliary transport. Am J Physiol Gastrointest Liver Physiol 272:G2185-G1303.
238. Murata M, Tamai I, Kato H, Nagata O, Kato H, and Tsuji A (1999) Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. J Pharmacol Exp Ther 290:51-57.
239. Nagata Y, Kusuhara H, Endou H, and Sugiyama Y (2002) Expression and functional characterization of rat organic anion transporter 3 (Slc22a8) in the choroid plexus. Mol Pharmacol 61:982-988.
240. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, and Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861-867.
241. Nakanishi T, Tamai I, Sai Y, Sasaki T, and Tsuji A (1997) Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res 58:4118-4122.
242. Nakanishi T, Tamai I, Takagi A, and Tsuji A (2000) Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer 83:274-280.
243. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y, Koizumi A, Shoji Y, et al. (1999) Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 21:91-94.
244. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, and Kivisto KT (2001) Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 69:400-406.
245. Nies AT, Konig J, Cui Y, Brom M, Spring H, and Keppler D (2002) Structural requirements for the apical sorting of human multidrug resistance protein 2 (ABCC2). Eur J Biol Chem 269:1866-1876.
246. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, and Sugiyama Y (1999) Primary active transport of organic anions on bile canalicular membrane in humans. Am J Physiol Gastrointest Liver Physiol 276: G1153-G1164.
247. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, et al (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565.
248. Nozawa T, Nakajima M, Tamai I, Noda Y, Nezu J, Sai Y, Tsuji A, and Yokoi T (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804-813.
249. Oguchi H, Miyasaka M, Koiwai T, Tokunaga S, Hara K, Sato K, Yoshie T, Shioya H, and Furuta S (1993) Pharmacokinetics of temocapril and enalapril in patients with various degree of renal insufficiency. Clin Pharmacokinet 24:421-427.
250. Oguri T, Fujiwara Y, Isobe T, Katoh O, and Yamakido M (1998) Expression of γ-glutamylcysteine synthetase (γ-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br J Cancer 77:1089-1096.
251. Oh DM, Han HK, and Amidon GL (1999) Drug transport and targeting. Intestinal transport. Pharm Biotechnol 12:59-88.
252. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, and Terasaki T (2002) Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83:57-66.
253. Okudaira N, Komiya I, and Sugiyama Y (2000) Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine. J Pharmacol Exp Ther 295:717-723.
254. Okudaira N, Tatebayashi T, Speirs GC, Komiya I, and Sugiyama Y (2000) A study of the intestinal absorption of and ester type prodrug, ME3229 in rats: active efflux transport as a cause of poor bioavailability of the active drug. J Pharmacol Exp Ther 294:580-587.
255. Oude Elferink RPJ, Meijer DKF, Kuipers F, Jansen PLM, Groen AK, and Groothuis GMM (1995) Hepatobiliary secretion of organic compounds: molecular mechanisms of membrane transport. Biochim Biophys Acta 1241:215-268.
256. Overbosch D, Van Gulpen C, Hermans J, and Mattie H (1988) The effect of probenecid on the renol tubular excretion of benzylpenicillin. Br J Clin Pharmacol 25:51-58.
257. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, and Sarkadi B (2001) Functional characterization of the human multidrug transporter, abcg2, expressed in insect cells. Biochem Biophys Res Commun 285:111-117.
258. Paulusma CC, Bosma PJ, Zaman GJR, Bakker CTM, Otter M, Scheffer GL, Scheper RJ, Borst P, and Oude Elferink RPJ (1996), Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Wash DC) 271:1126-1128.
259. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst P, Baas F, and Oude Elferink RP (1997) A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25:1539-1542.
260. Paulusma CC, Kothe MJ, Bakker CT, Bosma PJ, van Bokhoven I, van Marle J, Bolder U, Tytgat GN, and Oude Elferink RP (2000) Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 31:684-693.
261. Perry CM and Noble S (1998) Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461-486.
262. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, and Falloon J (2000) Indinavir concentrations and St John's Wort. Lancet 355:547-548.
263. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, and Meier PJ (2002) Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 16:2283-2296.
264. Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL, and Muller M (2002) Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 35:589-596.
265. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
266. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, and Greenberger LM (1998) Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58:5850-5858.
267. Reichel C, Gao B, Van Montfoort J, Cattori V, Rahner C, Hagenbuch B, Stieger B, Kamisako T, and Meier PJ (1999) Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology 117:688-695.
268. Roberts SA (2001) High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 31:557-589.
269. Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE, and Schneider E (2000) The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun 271:42-46.
270. Roelofsen H, Soroka CJ, Keppler D, and Boyer JL (1998) Cyclic AMP stimulates sorting of the canalicular organic anion transporter (Mrp2/cMoat) to the apical domain in hepatocyte couplets. J Cell Sci 111:1137-1145.
271. Rost D, Kartenbeck J, and Keppler D (1999) Changes in the localization of the rat canalicular conjugate export pump Mrp2 in phalloidin-induced cholestasis. Hepatology 29:814-821.
272. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Hendricks C, Rock MK, and Donehower RC (1994) Phase I and pharmacological study of novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidinol carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436.
273. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, and Tewksbury DA (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74:834-841.
274. Russel FG, Masereeuw R, and van Aubel RA (2002) Molecular aspects of renal anionic drug transport. Annu Rev Physiol 64:563-594.
275. Sadeque AJM, Wandel C, He H, Shah S, and Wood AJJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
276. Saito H and Inui K (1995) Dipeptide transporters in apical and basolateral membranes of the human intestinal cell line Caco-2. Am J Physiol Gastrointest Liver Physiol 265:G289-G294.
277. Sasabe H, Tsuji A, and Sugiyama Y (1998) Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther 284:1033-1039.
278. Sasaki M, Suzuki H, Ito K, Abe T, and Sugiyama Y (2002) Transcellular transport of organic anions across double-transfected MDCK II cell monolayer expressing both human organic anion transporting polypeptide (OATP2/SLC21A6) and multidrug resistance associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497-6503.
279. Sathirakul K, Suzuki H, Yasuda K, Hanano M, Tagaya O, Hori T, and Sugiyama Y (1993) Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. J Pharmacol Exp Ther 265:1301-1312.
280. Sawada K, Terada T, Saito H, Hashimoto Y, and Inui K (1999) Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J Pharmacol Exp Ther 291:705-709.
281. Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, and McDonald M (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73:1268-1271.
282. Schinkel AH (2001) The role of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol 500:365-372.
283. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
284. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JM, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
285. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJM, and Borst P (1995a) Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A:1295-1298.
286. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, et al. (1994) Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
287. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
288. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995b) Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Investig 96:1698-1705.
289. Schwarz UI, Gramatte T, Krappweis J, Oertel R, and Kirch W (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161-167.
290. Seelig A and Landwojtowicz E (2000) Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31-40.
291. Seitz S, Kretz-Rommel A, Oude Elferink RP, and Boelsterli UA (1998) Selective protein adduct formulation, of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 11:513-519.
292. Sekine T, Cha SH, and Endou H (2000) The multispecific organic anion transporter (OAT) family. Pflueg Arch 440:337-350.
293. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, and Endou H (1998) Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 429:179-182.
294. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, and Endou H (1997) Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272:18526-18529.
295. Sheng M and Sala C (2001) PDZ domains and the organization of supramolecular complex. Annu Rev Neurosci 24:1-29.
296. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
297. Shoda J, Kano M, Oda K, Kamiya J, Nimura Y, Suzuki H, Sugiyama Y, Miyazaki H, Todoroki T, Stengelin S, et al. (2001) The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am J Gastroenterol 96:3368-3378.
298. Siedlik PH, Olson SC, Yang BB, and Stern RH (1999) Erythromycin coadministration increases plasma atrovastatin concentrations. J Clin Pharmacol 39:501-504.
299. Sikic BI, Advani R, Fisher GA, Halsey J, Cohen P, and Lum BL (2000) Enhanced bioavailability of oral paclitaxel by valspodar (PSC833), an inhibitor of small bowel P-glycoprotein and cytochrome P450. Clin Cancer Res 6:4580S.
300. Simon FR, Fortune M, Iwahashi S, Bowman A, Wolkoff A, and Sutherland E (1999) Characterization of the mechanisms involved in the gender differences in hepatic taurocholate uptake. Am J Physiol Gastrointest Liver Physiol 276:G556-G565.
301. Simons NL, Humter J, and Jepson MA (1997) Renal secretion of xenobiotics mediated by P-glycoprotein: importance to renal function in health and exploitation for targeted drug delivery to epithelial cysts in polycystic kidney disease. Adv Drug Deliv Rev 25:243-256.
302. Simonson GD, Vincent AC, Roberg KJ, Huang Y, and Iwanij V (1994) Molecular cloning and characterization of a novel liver-specific transport protein. J Cell Sci 107:1065-1072.
303. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, and Schinkel AH (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure, J Clin Investig 104:1441-1447.
304. Sokol RJ, Johnson KE, Karrer FM, Narkewiez MR, Smith D, and Kam I (1991) Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 338:212-214.
305. SoRelle R (2001) Baycol withdrawn from market. Circulation 104:E9015-E9016.
306. Soroka CJ, Lee JM, Azzaroli F, and Boyer JL (2001) Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and choloingiocytes during obstructive cholestasis in rat liver. Hepatology 33:783-791.
307. Spahn-Langguth H and Langguth P (2001) Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361-367.
308. Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, et al. (1999) Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10:719-728.
309. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, et al. (2001b) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98:3369-3374.
310. Staudinger J, Liu Y, Madan A, Habeebu S, and Klaassen CD (2001a) Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 29:1467-1472.
311. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430.
312. Stockel B, Konig J, Nies AT, Cui Y, Brom M, and Keppler D (2000) Characterization of the 5′-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison with the multidrug resistance protein 3 (MRP3) gene. Eur J Biochem 267:1347-1358.
313. Stouch TR and Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54:315-328.
314. St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ, and Stallmach T (2002) Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 87:1856-1863.
315. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, and Sugiyama Y (2001) Characterization of the efflux transport of 17β-estradiol-D-17β-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther 298:316-322.
316. Sun H, Dai H, Shaik N, and Elmquist WF (2003) Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83-105.
317. Suzuki H and Sugiyama Y (1999) Transporters for bile acids and organic anions, in Membrane Transporters as Drug Targets (Sadee W and Amidon G eds) pp. 387-439, Kluwer Academic/Plenum Publishing Co, New York.
318. Suzuki H and Sugiyama Y (2000) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
319. Suzuki H and Sugiyama Y (2002) Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 54:1311-1331.
320. Suzuki H, Terasaki T, and Sugiyama Y (1997) Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv Drug Deliv Rev 25:257-285.
321. Swaan PW, Stebouwer MC, and Tukker JJ (1995) Molecular mechanism for the relative binding affinity to the intestinal peptide carrier: comparison of three ACE-inbibitors, enalapril, enalaprilat and lisinopril. Biochim Biophys Acta 1236: 31-38.
322. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, and Nigam SK (2002) Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 [Slc22a8]) knockout mice. J Biol Chem 277:26934-26943.
323. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590.
324. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, and Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164-170.
325. Takano M, Hasegawa R, Fukuda T, Yamoto R, Nagai J, and Murakami T (1998) Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358:289-294.
326. Takeda M, Babu E, Narikawa S, and Endou H (2002a) Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 438: 137-142.
327. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, and Endou H (2002b) Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302: 666-671.
328. Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, and Endou H (1999) Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. Kidney Int 56:2128-2136.
329. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, and Tsuji A (2000a) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251-260.
330. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, and Tsuji A (2001) Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res (NY) 18:1262-1269.
331. Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, and Tsuji A (1995) Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res (NY) 12:1727-1732.
332. Tamai I and Tsuji A (2000) Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 89:1371-1388.
333. Tamai I, Yamashita J, Kido Y, Ohnari A, Sai Y, Shima Y, Naruhashi K, Koizumi S, and Tsuji A (2000b) Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 295:146-152.
334. Tanaka T, Uchiumi T, Hinoshita E, Inokuchi A, Toh S, Wada M, Takano H, Kohno Y, and Kuwano M (1999) The human multidrug resistance protein 2 gene: functional characterization of the 5′-flanking region and expression in hepatic cells. Hepatology 30:1507-1712.
335. Terada T, Saito H, Murai M, and Inui K (1997) Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol Renal Physiol 273:F706-F711.
336. Thyss A, Milano G, Kubar J, and Namer M (1986) Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen, Lancet 1:256-258.
337. Tiberghien F and Loor F (1996) Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 7:568-578.
338. Tirona RG and Kim RB (2002) Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 54:1343-1352.
339. Tirona RG, Leake BF, Merino G, and Kim RB (2001) Polymorphisms in oatp-c. Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669-35675.
340. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, and Brater DC (1992) The effects of a salicylate, ibuprofen and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 42:121-125.
341. Troutman MD, Luo G, Gan LS, and Thakker DR (2001) The role of P-glycoprotein in drug disposition: significance to drug development, in Drug-Drug Interactions (Rodrigues AD ed) pp. 295-358, Marcel Dekker, New York.
342. Tsuda M, Sekine T, Takeda M, Cha SH, Kanai Y, Kimura M, and Endou H (1999) Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther 289:1301-1305.
343. Tsuji H, Konig J, Rost D, Stockel B, Leuschner U, and Keppler D (1999) Exon-intron organization of the human multidrug resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 117:653-660.
344. Tsuji A and Tamai I (1996) Carrier-mediated intestinal transport of drugs. Pharm Res (NY) 13:963-977.
345. Tsuji A and Tamai I (1997) Blood-brain barrier function of P-gp. Adv Drug Deliv Rev 25:285-298.
346. Tsuji A, Terasaki T, Tamai I, and Takeda K (1990). In vivo evidence for carrier-mediated uptake of beta-lactam antibiotics through organic anion transport systems in rat kidney and liver. J Pharmacol Exp Ther 253:315-320.
347. Turriziani O, Marco PD, and Antonelli G (2000) May the drug transporter P-glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 protease inhibitors? Antimicrob Agents Chemother 44:473-474.
348. Ueda K, Kato Y, Komatsu K, and Sugiyama Y (2001) Inhibition of the biliary excretion of methotrexate by probenecid in rats: quantitative prediction of the interaction from in vitro data. J Pharmacol Exp Ther 297:1036-1043.
349. Urakami Y, Nakamura N, Takahashi K, Okuda H, Saito Y, Hashimoto Y, and Inui K (1999) Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett 461:339-342.
350. Urakami Y, Okuda M, Masuda S, Saito H, and Inui K (1998) Functional characteristics and membrane localization of rat multispecific organic cation transporters, oct1 and oct2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 287:800-805.
351. Uwai Y, Okuda M, Takami K, Hashimoto Y, and Inui K (1998) Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett 438:321-324.
352. Uwai Y, Saito H, Hashimoto Y, and Inui K (2000) Interaction and transport of thiazide diuretics, loop diuretics and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther 295:261-265.
353. van Aubel RAMH, Masereeuw R, and Russel FGM (2000) Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol 279:F216-F232.
354. van Zuylen L, Verweij J, and Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Investig New Drugs 19:125-141.
355. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al. (2001) The sequence of the human genome. Science (Wash DC) 291:1304-1351.
356. Vos TA, Ros JE, Havinga R, Moshage H, Kuipers F, Jansen PL, and Muller M (1999) Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. Hepatology 29:1833-1839.
357. Wacher VJ, Salphati L, and Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89-102.
358. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
359. Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, and Endou H (2000) Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir and other antiviral nucleoside analogs. J Pharmacol Exp Ther 294:844-849.
360. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, and Inui K (1998) Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 64:123-128.
361. Walters HG, Craddock AL, Fusegawa H, Willingham MC, and Dawson PA (2000) Expression, transport properties and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol 279:G1188-G1200.
362. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR, and Wood AJJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
363. Wang EJ, Casciano CN, Clement RP, and Johnson WW (2000) In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 28:316-322.
364. Wang D, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, and Sugiyama Y (2002) Involvement of organic cation transporter 1 in the hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510-515.
365. Wang D, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, and Sugiyama Y (2003) Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63:1-5.
366. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, and Siegmund W (2000a) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6-12.
367. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, et al. (2000b) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug-drug interaction. Clin Pharmacol Ther 68:345-355.
368. White RE (2000) High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 40:133-157.
369. Wijnholds J, de Lange ECM, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, and Borst P (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Investig 105:279-285.
370. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, and Borst P (1997) Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3:1275-1279.
371. Wu X, Huang W, Prasad PD, Seth P, Pajan DP, Leibach FH, Chen J, Conway SJ, and Ganapathy V (1999) Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2) and organic cation/carnitine transporter. J Pharmacol Exp Ther 290:1482-1492.
372. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, and Ganapathy V (1998) Identity of organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 273:32776-32786.
373. Wu X, Whitfield LR, and Stewart BH (2000) Atrovastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid cotransporter. Pharm Res (NY) 17:209-215.
374. Yamaguchi H, Yano I, Hashimoto Y, and Inui K (2000) Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. J Pharmacol Exp Ther 295:360-366.
375. Yamazaki M, Neway WE, Ohe T, Chen IW, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.
376. Yamazaki M, Suzuki H, and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res (NY) 13:497-513.
377. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K, and Tsuji A (1999) P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdrla knockout mice. Pharm Res (NY) 16:1213-1218.
378. Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203-1211.
379. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, and Coggin M (1999) Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res (NY) 16:1812-1817.
380. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, and Takano M (1999) Transport of Rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149-155.
381. Zhang Y and Benet LZ (1998) Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res (NY) 15:1520-1524.
382. Zhang Y and Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168.
383. Zhang L, Brett CM, and Giacomini KM (1998) Role of organic cation transporters in drug absorption and elimination. Ann Rev Pharmacol Toxicol 38:431-460.
384. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, and Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51:913-921.
385. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer K, et al. (2001) The human pregnane X receptor: genomics structure and identification and fictional characterization of natural allelic variants. Pharmacogenetics 11:555-572.
386. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner K, Ferenci P, Stauber RE, Krejs GJ, Denk H, et al. (2001) Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33:633-646.